217 results about "Cell phenotype" patented technology

The invention provides a tumor detection data analysis method based on a peripheral blood immune marker, and belongs to the technical field of immunodetection.The tumor detection data analysis method comprises the steps that firstly, a peripheral blood sample of a patient is collected, and plasma and cell components are separated; analyzing various immune cell phenotypes by using flow cytometry; determining the concentration of key cell factors; analyzing the molecular expression level of the immune checkpoint; establishing an immune cell subset proportion empirical function; analyzing a cell factor expression mode by using an immune lineage transcriptome analysis model; establishing a tumor immune microenvironment score by combining the immune cell subset proportion and a model output result; the accuracy of the scoring system is verified through clinical follow-up visit and iconography examination; a standardized report template is formulated to provide a tumor early detection basis. Wherein the immune lineage transcriptome analytical model adopts a multi-modal attention fusion network architecture, three different immune data streams can be processed and integrated at the same time, and accurate evaluation of tumor-related immune states is realized.

The invention provides an in-vitro culture method of T cells, and belongs to the technical field of genetic engineering.The culture method comprises the steps that immune cell serum-free culture media are added into peripheral blood mononuclear cells, and activated culture is conducted in the presence of cell factors to obtain activated T cells; the cell factor comprises an IL-2 monoclonal antibody and a CD3 monoclonal antibody, and further comprises two or three of an iCAM1 protein, a CCL21 protein and OK432. The T cells obtained through activation and multiplication culture are relatively stable in cell phenotype, relatively large in amplification multiple, relatively high in cell viability and relatively high in tumor killing efficiency. T cells are obtained after activation is performed for 24 hours and then multiplication culture is performed for 14 days, and the number of the cells is 6.2-8.9 * 10 < 9 >; the killing rate on Hela cells is 51.9 to 74.1 percent, and the killing rate on LOVO cells is 55.7 to 80.5 percent.

The invention relates to the technical field of classified storage of biological data, in particular to a classified storage method and system for biological cell data. The method comprises the following steps: acquiring multisource cytomics data; performing data standardization on the multisource cytomics data to obtain standard cell characteristic data; performing characteristic matrix conversion on the standard cell characteristic data to obtain a cell characteristic digital matrix; performing molecular fingerprint construction on the biological cells based on the cell characteristic digital matrix to obtain cell molecular characteristic fingerprint data; performing hierarchical classification on the standard cell characteristic data to obtain a cell phenotype classification system; performing hierarchical labeling on the standard cell characteristic data according to the cell phenotype classification system to obtain cell phenotype labeling data; and performing ontology mapping on the cell phenotype labeling data to obtain a cell phenotype relationship network. According to the method, refined classification, dynamic updating and efficient storage of the biological cell data are realized.

In some examples, a method includes using a machine learning encoder to extract respective sets of machine learning (ML)-based features from respective images of cells that are dying and unstained. Cells of a first subset are at a first state of dying, and cells of a second subset are at a second state of dying. The method may include using a computer vision encoder to extract respective sets of cell morphometric features from the respective images. The method may include using the respective sets of ML-based features and the respective sets of cell morphometric features to generate respective multi-dimensional feature vectors that represent respective cell phenotypes. The method may include using the respective multi-dimensional feature vectors to correlate, to the first state of dying or to the second state of dying, a phenotypic difference between the cells of the first subset and the cells of the second subset.

In some examples, a method of processing includes using a machine learning encoder to extract respective sets of machine learning (ML)-based features from respective images of viable, unstained cells. Cells of a first subset of the cells have a first genetic edit, and cells of a second subset of the cells lack the first genetic edit. The method may include using a computer vision encoder to extract respective sets of cell morphometric features from the respective images. The method may include using the respective sets of ML-based features and the respective sets of cell morphometric features to generate respective multi-dimensional feature vectors that represent respective cell phenotypes. The method may include using the respective multi-dimensional feature vectors to correlate, to the first genetic edit, a phenotypic difference between the cells of the first subset and the cells of the second subset.

Type 2 diabetes (T2D) is a clinical syndrome caused by insufficient insulin secretion for insulin requirements. Described herein are compositions and methods for microphysiological MPS models of disease (MODs) for diabetes. These platforms allow one to compare the effect of chronic β-cell stimulation in the presence and absence of patient specific immune cells in IPSC-derived islets from each group. Additionally, one can reproduce the T2D β-cell phenotype, using islets-on-chips will also be exposed to gluco-lipotoxicity. Likewise, skeletal muscle-on-chips are exposed to patient specific activated immune cells, variable motor neuron innervation and lipids characteristic of T2D.

The invention relates to the related technical field of primary cell (PDC) culture, in particular to a method for culturing primary cells (PDC) from glioma patients, which comprises a series of steps of Swis3T3-J2 cell culture, conditioned medium preparation, brain tumor tissue pretreatment, primary tumor cell digestion and culture and the like. Primary human tumor cells are cultured by a conditioned culture medium generated by fibroblasts irradiated by X-rays (X) and a cobalt-60 radioactive source (60Co), and culture conditions of key features of parent tumors and a modeling process can be most effectively reserved by screening and optimizing the culture conditions. And whether the PDC retains the key characteristics of the parent tumor or not is inspected on the aspects of the cell molecular level, the cell phenotype, the animal intracranial tumor model and the like.

The present application relates to the field of bioinformatics. In particular, the present application relates to methods and apparatus for speculating variable splicing functionality based on single cell transcriptome data. The method comprises the following steps: determining a variable splicing mode of each gene in a data set in a cell; determining the incidence relation between the variable splicing mode and the gene expression of each gene; a variable splicing mode module is determined according to the incidence relation between the variable splicing modes and the gene expression, and the variable splicing mode module is a variable splicing mode set obtained through clustering according to the correlation between the variable splicing modes and the cell phenotypes; displaying the cell splicing heterogeneity according to the variable splicing mode module; and / or determining a potential regulatory mechanism between the variable splicing mode and the gene expression according to the variable splicing mode module, the potential regulatory mechanism being used for embodying key splicing factors in the gene expression, and a biological approach in which the variable splicing mode affects the cell phenotype.

The present invention concerns a system for phenotypical profiling of at least one object and deterministic nanoliter-droplet encapsulation, comprising sample supplying means, buffer supplying means; a microfluidic chip comprising an encapsulation area or structure in which the object is encapsulated with a quantity of the reaction buffer by the droplet; detection means configured to detect the passage of the object through the first imaging chamber; at least one valve configured to stop the flow of the sample buffer when the detection means detect passage of the object through the first imaging chamber; phenotypical assessing means configured to assess the phenotype of the object when the flow of the sample buffer is stopped by the valve and the object is at an object stopping site; a droplet deposition means configured to deposit the droplet in a well or in a well of a multi-well plate and comprising an outlet capillary.

The present disclosure relates to methods for the production of a cell-based product based on using synthetic promoters or a cellular input-output unit thereof, configured for controlling the expression of at least one nucleic acid sequence of interest, upon sensing dynamic cellular- and / or environmental- state and / or condition, that leads to a desired phenotype of the cells. The present disclosure further provides cell-based products, in particular, animal cell-based meat products (ACBM).

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and / or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

The invention discloses application of Eucommia lignan in preparation of drugs for preventing and treating sepsis in the technical field of medicines. According to the scheme, the effects of the eucommia ulmoides lignan on the aspects of relieving sepsis inflammatory response, regulating cell phenotype and related protein gene expression, relieving neuron damage and the like are fully verified from the cell and animal levels, and the application value of the eucommia ulmoides lignan in preparation of the medicine for preventing and treating sepsis is proved.

Ex vivo cell-based living biosensors, methods of imaging and identifying cell types and / or cell phenotypes, and uses of the systems and methods are provided.

An imaging flow cytometry-based high-throughput drug screening method, comprising: cell incubation, cell staining, acquiring single-cell images by using a flow cytometer, and image extraction and analysis, which combines the high-throughput advantages of flow cytometry and the imaging capability of a microscope, so that multi-channel single-cell images can be generated in a high throughput manner, thereby implementing acquisition of fluorescent images and unmarked images of single cells at a throughput of 102-105 cells per second, which can be used for cell phenotype drug screening and improving the screening efficiency by a factor of 102-104.

The invention discloses a new application of human YTHDF1, namely an application of a human YTHDF1 gene expression quantity detection reagent in preparation of a prostatic cancer clinical diagnosis reagent. The expression of the human YTHDF1 gene in prostatic cancer tissues and cell lines is increased; after the expression of the YTHDF1 gene is knocked down, the growth of a prostate cancer cell line, the culture of organoids and the growth of transplanted tumors in nude mice are obviously inhibited; according to the present invention, with the application of the RNF7 in the tumor cells, the proliferation of the normal prostate epithelial cells can be promoted by the overexpression, the protein level of the RNF7 in the YTHDF1 knocked-down cells is significantly inhibited, the phenotype of the YTHDF1 knocked-down cells can be rescued by the overexpression of the RNF7, and the sensitivity of the tumor cells to the chemotherapeutic drugs can be promoted by the YTHDF1 knocked-down cells so as to promote the apoptosis; the prostatic cancer can be treated by inhibiting expression drugs of the human YTHDF1 gene, inhibiting expression of the E3 ubiquitin ligase RNF7 gene or screening drugs for degrading the E3 ubiquitin ligase RNF7.

The present disclosure provides a method of evaluating a mechanism of bipolar disorder, in particular mood switch, in human-derived neurons which may include providing a mechanism of an attenuated protein interaction of CaV1.2 and BK that can cause the calcium signaling deficit, the main cellular phenotype. The present disclosure further provides a method of evaluating a composition for efficacy in treating bipolar disorder, including providing a genetically modified mouse exhibiting BK channel haploinsufficiency; administering the composition to the genetically modified non-human animal; exposing the genetically modified mouse animal to a mild stressor; and determining whether the genetically modified mouse animal experiences a behavioral switch. The present disclosure also provides a method of treating bipolar disorder in a subject in need thereof, including administering to the subject a therapeutically effective amount of a BK channel agonist.

The invention belongs to the technical field of biological medicine, and particularly relates to a construction method of a gastric mucosa intestinal epithelial metaplasm type organ model with goblet cell phenotype. The model is characterized by MUC2 + MUC6 + goblet cells, and histological characteristics of gastric mucosa intestinal metaplasia are more deeply simulated from the aspect of cell phenotype. The construction method comprises the following steps: (1) obtaining a human stomach gland to prepare an organoid; (2) subculturing the organoid; (3) construction of a pCDH-CMV-MCS-EF1-CDX2-Puro overexpression lentiviral vector, and construction of a pCDH- (4) virus packaging; (5) constructing CDX2 overexpression stably transfected cells and organoid; and (6) carrying out gradient differentiation on the CDX2 overexpression organoid to prepare the intestinal metaplasia organoid. According to the invention, the pathological transformation of the cytology level in the gastrointestinal mucosa intestinal epithelial metaplasia process is realized in the in-vitro model for the first time, and a new research model and theoretical guidance are provided for the diagnosis, prevention and individualized precise treatment of precancerous lesions of gastric cancer.

Provided in some aspects are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA systems, that bind to or target a target site in a gene or regulatory element thereof in a T cell. In some aspects, the provided epigenetic modifying DNA-targeting systems provided herein modulate a T cell phenotype or activity. In particular, the provided embodiments relate to the transcriptional repression of genes to promote a stem cell-like memory T (TSCM) cell phenotype. In some aspects, also provided are compositions, polynucleotides, vectors, cells, and pluralities and combinations thereof, and methods and uses related to the provided epigenetic-modifying DNA-targeting systems, for example in modulating the phenotype in T cells including in connection with adoptive T cell therapy.

The invention provides an innovative screening method and application of key molecules in the occurrence and development process of intrahepatic cholangiocarcinoma. Firstly, transcriptome sequencing is performed on intrahepatic cholangiocarcinoma tissues and adjacent tissues corresponding to the intrahepatic cholangiocarcinoma tissues; and then, selecting a plurality of long-chain non-coding RNAs to carry out subsequent cell phenotype screening experiments according to the difference multiple of the sequencing results of the tumor and the adjacent tissue. And selecting the lncRNA capable of reducing the proliferation and / or invasion ability of the intrahepatic cholangiocarcinoma cells according to a screening experiment result, wherein the lncRNA is the key molecule in the occurrence and development process of the intrahepatic cholangiocarcinoma cells. Furthermore, in-vivo and in-vitro experiments prove that the targeted key molecules can inhibit the occurrence and development process of ICC, and meanwhile, the feasibility and effectiveness of a key molecule mining strategy in an intrahepatic cholangiocarcinoma occurrence and evolution mechanism are also verified. The invention aims to provide an innovative screening strategy for the exploration of key molecules in the ICC occurrence and development process so as to provide a beneficial thought for the early diagnosis and precise treatment of ICC.

In some examples, a method of processing includes using a machine learning encoder to extract respective sets of machine learning (ML)-based features from respective images of viable, unstained cells. Cells of a first subset of the cells have a first genetic edit, and cells of a second subset of the cells lack the first genetic edit. The method may include using a computer vision encoder to extract respective sets of cell morphometric features from the respective images. The method may include using the respective sets of ML-based features and the respective sets of cell morphometric features to generate respective multi-dimensional feature vectors that represent respective cell phenotypes. The method may include using the respective multi-dimensional feature vectors to correlate, to the first genetic edit, a phenotypic difference between the cells of the first subset and the cells of the second subset.

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, that bind to or target multiple genes or regulatory elements thereof, for instance in a T cell. In some aspects, the provided epigenetic-modifying DNA-targeting systems promote increased transcription of one or more first genes and promote repressed transcription of one or more second genes. In some aspects, the provided epigenetic-modifying DNA-targeting systems modulate a T cell function, such as a T cell phenotype or activity. Also provided herein are polynucleotides, vectors, cells, methods, and uses related to the provided epigenetic-modifying DNA-targeting systems, for example in modulating T cells, such as in connection with methods of adoptive T cell therapy.

The present invention relates generally to compositions, systems and methods for modulating hepatitis B virus (HBV) by targeting gene repression. In particular, the present invention provides an epigenetically modified DNA targeting system, such as a CRISPR-Cas / guide RNA (gRNA) system, for transcriptional repression of hepatitis B virus genes to promote cell phenotypes that lead to reduced HBV infection. In some embodiments, the epigenetically modified DNA targeting systems of the present invention bind to or target a target site of at least one gene in the hepatitis B virus DNA sequence or a regulatory element thereof in a cell. In some aspects, the systems provided herein relate to transcriptional repression of one or more hepatitis B virus genes and / or regulatory elements thereof. In some aspects, the invention also provides methods and uses associated with the provided compositions, such as in repression of hepatitis B virus replication and expression associated with hepatitis B infection.

Methods and processes disclosed herein generally involve training a machine learning model to identify a condition active in changing a cellular phenotype. In particular, cells having the cellular phenotype can be cultured in wells having a reference condition that changes the cellular phenotype, along with a background compound to provide a reference plurality, and cells having the cellular phenotype can be cultured in wells having a background compound to provide a non-reference plurality. A staining and imaging assay can be performed on the reference and non-reference pluralities after incubation, and the images are applied to a machine learning model to classify the results into activity data, to identify a "hit" activity plurality as corresponding to the reference plurality, and a "non-hit" activity plurality as corresponding to the non-reference plurality. The machine learning model can be used in a process to identify a test condition predicted to be active in changing a cell line phenotype.

A composition is provided comprising a cell population and pharmaceuticals derived from human gingival fibroblasts, present in proportions not found in natural gingival tissue, but having a cellular phenotype preferentially selected to express proteins favorable for angiogenesis and anti-inflammatory effects, while reducing the formation of cell populations that promote tumorigenesis and / or metalloproteinases that inhibit tissue regeneration. A method for producing such a composition that increases proliferation several times over compared to previously known methods is provided, and a method for using such a composition in a wide range of human cell therapies is also provided.

The invention provides an application and a method for inducing phenotype transformation from oral mucosa epithelium to dry lip epithelium by linoleic acid, linoleic acid with proper concentration acts on oral mucosa epithelial cells to regulate and control cell differentiation procedures, so that expression of specific markers of the oral mucosa epithelial cells is reduced, expression of specific markers of dry lip epithelial cells is increased, and expression of the specific markers of the oral mucosa epithelial cells is increased. The directional transformation of the cell phenotype is realized. The linoleic acid with the proper concentration is 10-20 [mu] M. The linoleic acid has the effects of regulating keratinization index expression of mucous membrane epithelial cells and enhancing the mucous membrane tissue barrier function for the first time, and the function is not recognized in previous research and clinical application of the linoleic acid.

The invention discloses an anti-loss type bionic spherical high-density lipoprotein preparation as well as a preparation method and application thereof. The bionic spherical high-density lipoprotein preparation mainly comprises the following components: phospholipid, auxiliary lipid, apolipoprotein, an anti-loss functional module and a protein stabilizer, and the particle size of the preparation is 7-50nm. The bionic spherical high-density lipoprotein preparation disclosed by the invention is simple in preparation process, has the particle size and appearance close to those of natural high-density lipoprotein, has an enzyme-like antioxidant property, can protect own lipid and protein components in inflammation and oxidative stress pathological environments and maintain the structure stability, maintains the function of the high-density lipoprotein, and has a good application prospect. The medicine leakage can be reduced when the medicine is used as a medicine carrier. When being applied to treatment of inflammatory diseases such as sepsis, atherosclerosis and the like, the compound can remarkably reduce the ROS level in cells, change the phenotype of inflammatory cells and improve the survival rate of animals, and a feasible treatment scheme is provided for treatment of the inflammatory diseases.

The invention discloses application of ACSS2 as an action target in screening or preparing a medicine for preventing or treating virus-induced vascular remodeling diseases, and belongs to the field of biological medicine. It is found that by inhibiting ACSS2 gene expression or protein activity, Zika virus induced vascular smooth muscle cell phenotypic transformation can be remarkably reversed, and occurrence and development of angiotensin II / aminopropionitrile induced aortic aneurysm / dissection are relieved. The invention provides a siRNA sequence (SEQ ID NO.1-2) specifically targeting ACSS2 and a pharmaceutical composition containing the siRNA, and provides a novel treatment target and a precise intervention tool for virus-related vascular remodeling diseases.

A method may include, by at least one data processor and based on a set of cytokinetic parameters corresponding to a plurality of T-cell phenotypes and the plurality of T-cell phenotypes, identifying a plurality of T-cell phenotypes in peripheral tissue and lymph node compartments (i.e., T-cell phenotypes, T-cell phenotypes, T-cell phenotypes, T-cell phenotypes, T-cell phenotypes, T-cell phenotypes, and T-cell phenotypes). The distribution of the plurality of T cell phenotypes over time is determined based on a transport rate between the plurality of T cell phenotypes (e.g., a healthy tissue compartment), a blood compartment, a tumor drainage lymph node compartment, and a tumor compartment. The plurality of T cell phenotypes may include stem cell-like memory T cells, central memory T cells, effector memory T cells, effector T cells, and endogenous T cells. Related methods and articles are also disclosed.

The present invention relates to a method for linking the genetic perturbations of individual cells within a cell population to the phenotype of the individual cells. The present invention also relates to a method for linking the expression of a gene or RNA of interest in individual cells within a cell population to the phenotype of the individual cells. The present invention furthermore relates to a nucleic acid molecule comprising in 5'-3' direction a U6 promoter, a gRNA and a T7 promoter reverse complement.

The invention relates to a drug effect evaluation method for fusing target molecules and time-concentration dependent cell phenotypes, which comprises the following steps: S1, preparing samples including a modeling sample and a to-be-detected sample; s2, carrying out FRET imaging and cell fluorescence imaging; s3, carrying out FRET image processing and FRET efficiency calculation; s4, cell fluorescence image processing and feature extraction; s5, calculating a phenotype characterization value; s6, calculating an FRET characterization value; s7, basic drug response value calculation; and S8, comprehensive drug effect evaluation. Target molecule information and time-concentration dependent cell phenotypic response are fused, a comprehensive drug effect evaluation model is constructed, the effect of drugs on whole cells is reflected, and whether the drugs target specified molecules or not is specifically indicated.